Liquid Chromatography Tandem Mass Spectrometry

液相色谱串联质谱法

• 批准号: 7595708
• 负责人: CHRISTINA C. WANG
• 金额: $ 48.74万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7595708
• 关键词: Arts; Biological Assay; Biomedical Research; Bone Diseases; California; Chemicals; Child; Clinical; Clinical Research; Core Facility; Diagnosis; Disease; Elderly; Endocrine; Equipment; Funding; HIV; Health Sciences; Hormonal; Hormones; Human; Immunoassay; Institutes; Institution; Joints; Kidney; Laboratories; Liquid Chromatography; Liquid substance; Los Angeles; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Measures; Medical center; Metabolic; Metabolic Bone Diseases; Metabolism; Methodology; Methods; Monitor; Morbidity - disease rate; Preparation; Protocols documentation; Reproducibility; Research; Research Institute; Research Personnel; Serum; Services; Sister; Technology; Translational Research; Underserved Population; United States National Institutes of Health; Universities; Vitamin Deficiency; Vitamins; Woman; mass spectrometer; men; patient population; programs; public health relevance; small molecule; tandem mass spectrometry

DESCRIPTION (provided by applicant): The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA Biomed) General Clinical Research Center (GCRC) is applying for a Liquid Chromatography Tandem Mass Spectrometer (LC-MS/MS) for the GCRC Core Laboratory and the Biomedical Mass Spectrometry Facility. The LC/MS/MS is requested to serve the needs of clinical and translational investigators at Harbor-LA Biomed and our sister institutions in Los Angeles (Cedars Sinai Medical Center (Cedars-Sinai), UCLA-Westwood, and the Charles Drew University of Health and Science (Drew)). The sharing of the services of this equipment is an important part of our preparation for a joint application for a Clinical and Translational Sciences Institute (CTSI) across the four sister institutions. To avoid duplication, increase efficiency and optimize utilization in the laboratory, the program and laboratories directors of the GCRCs at UCLA Westwood, Cedars-Sinai, Harbor-LA Biomed and Drew have agreed to designate the Harbor-UCLA GCRC Core Lab and Biomedical Mass Spectrometry facility as the central Endocrine and Metabolism Core Laboratory for all four CTSI institutions. Currently, the GCRC Core Laboratory provides hormone and vitamin analyses mostly by immunoassays. These methodologies have higher variance, poorer reproducibility and in many instances less accuracy than that obtained from LC/MS/MS. The challenges of clinical assays of small molecules in research include the requirements of high sensitivity and low limit of quantitation (LOQ) into the low fentomolar range. Such sensitivity is necessary in order to be able to accurately diagnose hormonal or vitamin deficiency and to monitor its treatment in men, women and children. Our current investigators include 6 major NIH users with 15 protocols, 9 NIH funded users and 6 other junior and funded investigators. These investigators are engaged in a wide spectrum of research spanning from metabolic bone diseases inflicting children and the elderly, hormonal deficiencies in men and women, hormone and non-hormone dependent cancers, co-morbidities of HIV disease and importantly, understanding mechanisms underlying these diseases. With expansion of validated assay portfolio we anticipate that we can support more than twice the research protocols. This application is strongly supported by all four participating institutions. The strengthening of the Core Facilities providing Mass Spectrometry Technology capability will also significantly enhance our ability to serve not only our institution but our sister institutions at UCLA, Cedars-Sinai, and Drew in Southern California and our diverse and often underserved patient population. PUBLIC HEALTH RELEVANCE: The Harbor-UCLA General Clinical Research Center is requesting the funding of a state of the art, high-throughput liquid chromatography tandem mass spectrometer to measure serum hormones and other metabolic products in human bodily fluids. This will allow the measurement of very small amounts of these hormones and chemicals with very high selectivity, accuracy and precision. The application of this method will support many investigators from LA BioMed, Cedars-Sinai, UCLA-Westwood and Drew University in the diagnosis and monitoring of treatment of many metabolic, endocrine, kidney an bone disease for our underserved population.

描述（由申请人提供）：Harbour-UCLA医学中心（LA BioMED）一般临床研究中心（GCRC）的洛杉矶生物医学研究所正在申请GCRC核心实验室和生物医学质谱设施的液相色谱串联量质谱仪（LC-MS/MS）。要求LC/MS/MS在Harbour-La Biomed和我们位于洛杉矶的姊妹机构（Cedars Sinai Medical Center（Cedars-Sinai），加州大学洛杉矶分校 - 西伍德（UCLA-Westwood）和查尔斯·德鲁·德鲁·德鲁（Charles Drew）的卫生与科学大学（DREW））的临床和转化调查员需求。该设备服务的共享是我们准备在四个姊妹机构中为临床和转化科学研究所（CTSI）共同申请的重要组成部分。为了避免重复，请提高实验室的效率并优化利用，在UCLA Westwood，Cedars-Sinai，Harbour-La BioMED和DREW的GCRC计划和实验室主管已同意将Harbour-Ucla GCRC核心实验室和生物医学质谱设施指定为中央官方核心和生物质谱机构，以供各种核心核心核心核心。目前，GCRC核心实验室主要通过免疫测定法提供激素和维生素分析。这些方法的差异较高，可重复性较差，并且在许多情况下的准确性比从LC/MS/MS获得的差异较低。研究中小分子的临床测定法的挑战包括高灵敏度和低量度限制（LOQ）对低探特奥尔尔范围的要求。为了能够准确诊断荷尔蒙或维生素缺乏症并监测其在男性，女性和儿童中的治疗方法，这种敏感性是必要的。我们目前的调查人员包括6位具有15个协议的NIH主要用户，9位由NIH资助的用户以及其他6名初级和资助的调查人员。这些研究者参与了各种研究，这些研究涵盖了造成儿童的代谢骨骼疾病，以及男性和女性的老年人，激素缺乏，激素和非激素依赖性癌症，HIV疾病的共生性，重要的是，了解这些疾病的机制。随着经过验证的测定组合的扩展，我们预计我们可以支持研究协议的两倍以上。该申请得到了所有四个参与机构的强烈支持。提供质谱技术能力的核心设施的加强也将显着增强我们不仅可以为我们的机构服务，而且还可以增强我们在UCLA，Cedars-Sinai的姊妹机构的服务能力，并在南加州以及我们多样化且经常服务不足的患者人数的能力。公共卫生相关性：港口 - 乌克拉群岛一般临床研究中心要求提供最先进的状态，高通量液相色谱串联质谱仪，以测量人体体液中的血清激素和其他代谢产物。这将允许以非常高的选择性，准确性和精度来测量非常少量的这些激素和化学物质。这种方法的应用将支持来自La Biomed，Cedars-Sinai，UCLA-Westwood和Drew University的许多研究人员，以诊断和监测许多代谢，内分泌，肾脏肾脏疾病的治疗，以供我们服务不足的人群进行骨骼疾病。